4D Molecular Therapeutics, Inc.
FDMT
$6.12
-$0.06-0.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.84% | -99.89% | -99.82% | -99.92% | 785.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.84% | -99.89% | -99.82% | -99.92% | 785.20% |
| Cost of Revenue | 53.60% | 50.30% | 45.54% | 34.23% | 28.22% |
| Gross Profit | -87.83% | -87.72% | -84.98% | -76.02% | -7.67% |
| SG&A Expenses | 23.46% | 26.85% | 27.61% | 28.49% | 21.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.51% | 43.86% | 40.64% | 32.67% | 26.47% |
| Operating Income | -67.91% | -68.18% | -66.43% | -60.46% | -11.72% |
| Income Before Tax | -78.49% | -68.75% | -59.53% | -49.56% | 1.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.49% | -68.75% | -59.53% | -49.56% | 1.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.49% | -68.75% | -59.53% | -49.56% | 1.32% |
| EBIT | -67.91% | -68.18% | -66.43% | -60.46% | -11.72% |
| EBITDA | -70.27% | -70.57% | -68.58% | -62.39% | -11.37% |
| EPS Basic | -53.99% | -30.87% | -12.36% | -3.57% | 30.42% |
| Normalized Basic EPS | -53.98% | -30.87% | -12.36% | -3.58% | 30.42% |
| EPS Diluted | -53.99% | -30.87% | -12.36% | -3.57% | 30.42% |
| Normalized Diluted EPS | -53.98% | -30.87% | -12.36% | -3.58% | 30.42% |
| Average Basic Shares Outstanding | 17.50% | 28.65% | 38.14% | 39.21% | 39.54% |
| Average Diluted Shares Outstanding | 17.50% | 28.65% | 38.14% | 39.21% | 39.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |